KR20040027927A - 심장 및 대사 장애의 치료를 위해 주요 환이 치환된갑상선 수용체 길항근 - Google Patents

심장 및 대사 장애의 치료를 위해 주요 환이 치환된갑상선 수용체 길항근 Download PDF

Info

Publication number
KR20040027927A
KR20040027927A KR10-2004-7002447A KR20047002447A KR20040027927A KR 20040027927 A KR20040027927 A KR 20040027927A KR 20047002447 A KR20047002447 A KR 20047002447A KR 20040027927 A KR20040027927 A KR 20040027927A
Authority
KR
South Korea
Prior art keywords
hydroxy
dibromo
isopropyl
phenyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7002447A
Other languages
English (en)
Korean (ko)
Inventor
죠한 마림
피터 브렌드트
카린 에드빈손
콘라드 코에힐레르
사닌안드레이
산드라 고르돈
Original Assignee
카로 바이오 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0120691A external-priority patent/GB0120691D0/en
Priority claimed from GB0207719A external-priority patent/GB0207719D0/en
Application filed by 카로 바이오 아베 filed Critical 카로 바이오 아베
Publication of KR20040027927A publication Critical patent/KR20040027927A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/205—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C07C65/26—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
KR10-2004-7002447A 2001-08-24 2002-08-13 심장 및 대사 장애의 치료를 위해 주요 환이 치환된갑상선 수용체 길항근 Ceased KR20040027927A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0120691.1 2001-08-24
GB0120691A GB0120691D0 (en) 2001-08-24 2001-08-24 Novel Compounds
GB0207719A GB0207719D0 (en) 2002-04-03 2002-04-03 Novel compounds
GB0207719.6 2002-04-03
PCT/EP2002/009120 WO2003018515A2 (en) 2001-08-24 2002-08-13 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders

Publications (1)

Publication Number Publication Date
KR20040027927A true KR20040027927A (ko) 2004-04-01

Family

ID=26246475

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7002447A Ceased KR20040027927A (ko) 2001-08-24 2002-08-13 심장 및 대사 장애의 치료를 위해 주요 환이 치환된갑상선 수용체 길항근

Country Status (8)

Country Link
US (1) US7279593B2 (https=)
EP (1) EP1499578A2 (https=)
JP (1) JP2005507381A (https=)
KR (1) KR20040027927A (https=)
AU (1) AU2002331145B2 (https=)
CA (1) CA2449515A1 (https=)
IL (1) IL159006A0 (https=)
WO (1) WO2003018515A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1435946B8 (en) * 2001-09-14 2013-12-18 Amgen Inc. Linked biaryl compounds
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
GB0406380D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
TWI534144B (zh) 2009-04-20 2016-05-21 田邊三菱製藥股份有限公司 甲狀腺荷爾蒙β受體作動藥
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
CA3075877A1 (en) 2017-09-14 2019-03-21 Riken Method for producing retinal tissues
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
KR20210138639A (ko) 2019-03-13 2021-11-19 다이니뽄 스미토모 세이야쿠 가부시키가이샤 이식용 신경 망막의 품질을 평가하는 방법 및 이식용 신경 망막 시트
EP4201428A4 (en) 2020-09-11 2024-09-11 Sumitomo Pharma Co., Ltd. MEDIUM FOR TISSUE INTENDED FOR TRANSPLANTATION
CA3194226A1 (en) 2020-09-11 2022-03-17 Riken Complex containing neural retina-containing cell aggregates and matrix, and method for manufacturing same
WO2023090427A1 (ja) 2021-11-19 2023-05-25 国立研究開発法人理化学研究所 シート状網膜組織の製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
EP0580550B1 (en) * 1992-07-21 1997-10-22 Novartis AG Oxamic acid derivatives as hypocholesteremic agents
EP0831769B2 (en) 1995-06-07 2008-07-23 Lavin, Dr., Thomas N. Novel uses for thyroid hormones or thyroid hormone-like compounds
GB9713739D0 (en) * 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
GB9816935D0 (en) * 1998-08-05 1998-09-30 Karobio Ab Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
GB9927056D0 (en) * 1999-11-17 2000-01-12 Karobio Ab Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
WO2001072692A1 (en) * 2000-03-31 2001-10-04 Pfizer Products Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
WO2001085670A1 (en) 2000-05-12 2001-11-15 Kissei Pharmaceutical Co., Ltd. Malonanilic acid derivatives, medicinal compositions containing the same and use thereof

Also Published As

Publication number Publication date
CA2449515A1 (en) 2003-03-06
EP1499578A2 (en) 2005-01-26
JP2005507381A (ja) 2005-03-17
IL159006A0 (en) 2004-05-12
AU2002331145B2 (en) 2008-07-10
WO2003018515A3 (en) 2004-10-28
US20050107347A1 (en) 2005-05-19
WO2003018515A2 (en) 2003-03-06
US7279593B2 (en) 2007-10-09

Similar Documents

Publication Publication Date Title
KR20040102080A (ko) 새로운 갑상선 수용체 리간드
KR20040017812A (ko) 심장병 환자 및 대사 장애를 위한 갑상선 호르몬 수용체길항근ⅱ
US7005538B1 (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
JP6437060B2 (ja) 縮合環類似体の抗線維症剤
TWI654172B (zh) 環烷基甲酸類衍生物、其製備方法及其在醫藥上的應用
KR20040027927A (ko) 심장 및 대사 장애의 치료를 위해 주요 환이 치환된갑상선 수용체 길항근
AU2002310850A1 (en) Thyroid hormone receptor antagonists for cardiac and metabolic disorders II
CN105209448A (zh) 三环化合物及其用途
KR20030072396A (ko) 갑상선 수용체 리간드
MXPA04008176A (es) Derivado de acido fenilalcanoico sustituido y uso del mismo.
CN104592145B (zh) 一种苯并氧化呋咱组蛋白去乙酰化酶抑制剂及其制备方法和应用
JP3341019B2 (ja) 選択的ロイコトリエンｂ▲４▼拮抗剤活性を示す置換された単環式アリール化合物
AU2002237298A1 (en) Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
AU2002331145A1 (en) Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
CN103848795B (zh) 一种1,2,5-噁二唑-2-氧化物组蛋白去乙酰化酶抑制剂及其制备方法和应用
TW201843135A (zh) 胺基-芳基-苯甲醯胺化合物及其使用方法
CN1332921C (zh) 治疗心脏和代谢紊乱的主环取代的甲状腺受体拮抗物
CN108440278B (zh) 一种二羧基查尔酮类化合物及其在制备抗炎药物中的应用
CN118026948A (zh) 三联芳环类化合物及其制备方法、药物组合物和应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040219

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070810

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080328

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20081111

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20080328

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I